Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Guardant Health, Inc. (Nasdaq: GH), a precision oncology company based in Palo Alto, California. Through these filings, investors and analysts can review the company’s official disclosures about its capital structure, governance, and key events related to its blood and tissue tests, real-world data activities, and AI analytics in cancer care.
Guardant Health’s common stock is registered on The Nasdaq Global Select Market under the symbol GH, as noted in its Form 8-K filings. The company files current reports on Form 8-K to describe material events, such as public offerings of common stock, private offerings of convertible senior notes, results of stockholder meetings, financial results announcements, and board appointments. These documents outline details like underwriting agreements, convertible note terms, and voting outcomes at annual meetings.
In addition to Form 8-K reports, Guardant Health files annual reports on Form 10-K and quarterly reports on Form 10-Q, which contain more extensive information about its business, risk factors, and financial statements. Proxy statements on Schedule 14A provide further detail on governance matters and executive compensation. Together, these filings offer a regulatory record of how the company finances its operations, manages its corporate governance, and communicates significant developments to the market.
On Stock Titan, Guardant Health’s SEC filings are updated as they are made available through the EDGAR system. AI-powered tools can help summarize long documents, highlight key terms in offerings and note indentures, and make it easier to locate information on topics such as capital raises, voting results, and reporting obligations. This page is intended as a convenient starting point for reviewing Guardant Health’s regulatory disclosures in one place.
Guardant Health (GH) reported an insider equity change. Director Roberto A. Mignone had 3,167 shares of Common Stock acquired on 10/21/2025 via a code M transaction, reflecting the conversion of restricted stock units at a price of $0.
Following the transaction, the filing lists 3,167 Common Stock shares beneficially owned in direct form. The derivative table shows 9,504 Restricted Stock Units beneficially owned after the event. The RSU grant from November 8, 2024 vests over four years: 25% on the one-year anniversary of October 21, 2024, with the remaining 75% vesting monthly over the next three years.
Guardant Health (GH) director Manuel Hidalgo Medina reported the vesting and settlement of restricted stock units into 232 shares of Common Stock on 10/17/2025 (transaction code M) at $0 per share.
Following the transaction, he directly owned 1,315 shares of Common Stock and held 7,657 RSUs outstanding. The RSU grant dated July 17, 2024 vests over four years: 25% vested on the one-year anniversary of July 17, 2024, with the remaining 75% vesting monthly over the next three years.
Guardant Health (GH) reported an insider transaction on a Form 4. A company director sold 116 shares of common stock at $66.95 on 10/17/2025. Following the sale, the reporting person directly holds 7,725 shares.
Guardant Health (GH) filed a Form 4 disclosing an insider sale. Director Myrtle S. Potter sold 26 shares of common stock on 10/17/2025 at $66.95 per share. After this transaction, she directly beneficially owns 18,324 shares. The filing lists the ownership form as direct and does not report any derivative security activity.
Guardant Health (GH)October 15, 2025, 69 shares of Common Stock were acquired at $0 upon the vesting and settlement of Restricted Stock Units (RSUs) (transaction code M). Following this, the director directly owned 18,350 shares.
The RSU award vested 25% on October 15, 2022, with the remaining 75% vesting in substantially equal monthly installments over the next three years.
Guardant Health (GH) director reports Form 4 activity. On 10/15/2025, 250 shares of common stock were acquired at $0 following the settlement of restricted stock units (transaction code M). After this transaction, the reporting person directly owns 7,841 shares.
The related derivative line shows 250 restricted stock units converted into 250 shares at $0 on 10/15/2025, leaving 4,248 derivative securities (restricted stock units) directly beneficially owned after the event.
The award referenced in the footnotes was granted on March 6, 2023 and vests over four years: 25% vested on the one-year anniversary of March 15, 2023, with the remaining 75% vesting monthly over the following three years.
Chris Freeman, Chief Commercial Officer of Guardant Health, Inc. (GH), reported multiple equity transactions dated 10/01/2025. He had 13,550 restricted stock units vest or be credited (1,928; 1,668; 9,954) and a separate purchase of 5,740 shares at $62.65. The company retained 5,740 shares to satisfy the tax withholding related to one vesting installment; the filer notes the retained amount did not exceed the tax liability. Following the reported transactions, Freeman beneficially owned 63,179 shares (direct ownership). The Form 4 was signed by an attorney-in-fact on behalf of Mr. Freeman on 10/02/2025.
Guardant Health director and Co‑Chief Executive Officer AmirAli Talasaz reported multiple transactions in the company's common stock. On 09/30/2025 he received 4,814 shares from vesting of restricted stock units and, separately the same day, 2,440 shares were retained by the company to satisfy tax withholding at a reported price of $62.48. On 10/01/2025 he received an additional 23,997 vested shares and 12,162 shares were retained for tax withholding at $62.65. After these reported transactions his beneficial ownership rose to 2,010,036 shares.
Steve E. Krognes, a director of Guardant Health, Inc. (GH), reported a transaction dated 09/30/2025 in which 154 shares were acquired following vesting of restricted stock units. The Form 4 shows the acquisition price as $0, reflecting conversion of vested RSUs into common stock. After the transaction, the filing reports 18,282 shares of common stock beneficially owned by Mr. Krognes and 1,389 RSU-linked derivative shares reported as beneficially owned. The RSU award was originally granted on 08/09/2022 and vested 25% on 06/30/2023, with the remaining 75% vesting in substantially equal monthly installments over the following three years. The Form 4 is signed by an attorney-in-fact on behalf of Mr. Krognes on 10/02/2025.
Helmy Eltoukhy, Co-Chief Executive Officer and director of Guardant Health (GH), reported multiple transactions on 09/30/2025 and 10/01/2025. He had restricted stock units vest that resulted in acquisitions of 4,814 and 23,997 shares (reported as acquisitions at $0), with the company retaining 2,440 and 12,162 shares respectively to satisfy tax-withholding obligations related to the vesting (sales at $62.48 and $62.65). After the reported activity, his beneficial ownership of common stock is shown as 2,149,870 shares following the 10/01/2025 transactions and 119,986 RSU-equivalent shares remaining reported as derivative holdings. The Form 4 is signed by an attorney-in-fact on behalf of Mr. Eltoukhy.